doxazosin has been researched along with Cardiovascular Stroke in 26 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 20 (76.92) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, K | 1 |
| Singh, N | 1 |
| Dhawan, RK | 1 |
| Hernández-Montoliu, L | 1 |
| Simó-Servat, A | 1 |
| Villabona, C | 1 |
| Davis, BR | 6 |
| Kostis, JB | 1 |
| Simpson, LM | 2 |
| Black, HR | 1 |
| Cushman, WC | 1 |
| Einhorn, PT | 2 |
| Farber, MA | 1 |
| Ford, CE | 4 |
| Levy, D | 1 |
| Massie, BM | 2 |
| Nawaz, S | 1 |
| Haywood, LJ | 1 |
| Crow, RS | 1 |
| Williard, A | 1 |
| Chapman, N | 1 |
| Chen, CY | 1 |
| Fujita, T | 1 |
| Hobbs, FD | 1 |
| Kim, SJ | 1 |
| Staessen, JA | 1 |
| Tanomsup, S | 1 |
| Wang, JG | 1 |
| Williams, B | 1 |
| Lynch, AI | 1 |
| Eckfeldt, JH | 1 |
| Boerwinkle, E | 1 |
| Leiendecker-Foster, C | 1 |
| Arnett, DK | 1 |
| Düsing, R | 2 |
| Tepliakov, AT | 1 |
| Gavrilova, NV | 1 |
| Garganeeva, AA | 1 |
| Cheng, TO | 1 |
| Piller, LB | 2 |
| Cutler, JA | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Yusuf, S | 1 |
| Westheim, A | 1 |
| SoRelle, R | 1 |
| Messerli, FH | 2 |
| Miller, JL | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Grossman, E | 1 |
| Hansson, L | 1 |
| Jeong, MH | 1 |
| Park, JC | 2 |
| Rhew, JY | 1 |
| Kang, KT | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Kim, NH | 1 |
| Kim, KH | 1 |
| Ahn, YK | 1 |
| Bae, Y | 1 |
| Cho, JG | 1 |
| Kim, SH | 1 |
| Kang, JC | 1 |
| Schillaci, G | 1 |
| Verdecchia, P | 1 |
| Pressel, SL | 1 |
| Wright, JT | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Bettencourt, J | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Nwachuku, C | 1 |
| Furberg, CD | 1 |
| Barzilay, JI | 1 |
| Jones, CL | 1 |
| Basile, JN | 1 |
| Goff, DC | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 1 |
| Verma, SP | 1 |
| Silke, B | 1 |
| Reynolds, GW | 1 |
| Kelly, JG | 1 |
| Richmond, A | 1 |
| Taylor, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for doxazosin and Cardiovascular Stroke
| Article | Year |
|---|---|
Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2010 |
10 trials available for doxazosin and Cardiovascular Stroke
| Article | Year |
|---|---|
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Comorbidity; Doxazosin; Humans; Hydrox | 2009 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
[Can antihypertensive treatment prevent myocardial infarction?].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Humans; Myocardial Infarction | 1993 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Antihypertensive Agents; Chlortha | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
15 other studies available for doxazosin and Cardiovascular Stroke
| Article | Year |
|---|---|
Potential role of EphrinA2 receptors in postconditioning induced cardioprotection in rats.
Topics: Animals; Creatine Kinase; Disease Models, Animal; Doxazosin; Female; Hemodynamics; Isolated Heart Pr | 2020 |
Tako-Tsubo cardiomyopathy induced by pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Atrial Fibrillation; Diagnosis, Differential; Doxazosi | 2018 |
[Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2003 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Effects of monotherapy with an alpha1-adrenoblocker doxazosin and its combination with beta1-adrenoblocker atenolol on hemodynamics, reversible myocardial ischemia in postmyocardial infarction patients with arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 2003 |
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as | 2006 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Doxazosin dropped from ALLHAT study.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Ca | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
First-line antihypertensive therapy.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Myocardial Infarction; Randomized Control | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, | 1992 |